Literature DB >> 33191284

Concerns, Healthcare Use, and Treatment Interruptions in Patients With Common Autoimmune Rheumatic Diseases During the COVID-19 Pandemic.

Michael D George1, Shilpa Venkatachalam2, Shubhasree Banerjee3, Joshua F Baker3, Peter A Merkel3, Kelly Gavigan2, David Curtis2, Maria I Danila4, Jeffrey R Curtis4, W Benjamin Nowell2.   

Abstract

OBJECTIVE: To assess concerns and healthcare-related behaviors of patients with autoimmune rheumatic diseases during the coronavirus disease 2019 (COVID-19) pandemic.
METHODS: Adults from the United States with rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and systemic lupus erythematosus (SLE) from the ArthritisPower Patient-Powered Research Network and CreakyJoints patient community completed surveys. Concerns and behaviors were compared among patients with different autoimmune conditions, disease-modifying antirheumatic drug (DMARD) use, and geographic measures of urban status, income, education, and COVID-19 activity.
RESULTS: Among 1517 participants (925 RA, 299 PsA, 185 AS, 108 SLE), mean age was 55.1 years, 88.3% were female, and 89.5% were White. COVID-19 concerns were similar across the country and were higher in biologic users (P < 0.001). Avoidance of doctor's office visits (56.6%) or laboratory testing (42.3%) and use of telehealth (29.5%) were more common in urban areas. Among participants receiving a DMARD without COVID-19 or other respiratory illness, 14.9% stopped a DMARD, with 78.7% of DMARD interruptions not recommended by a physician. DMARD stopping was more common in participants with lower socioeconomic status (SES) and in participants who avoided an office visit (OR 1.46, 95% CI 1.04-2.04) or reported lack of telehealth availability OR 2.26 (95% CI 1.25-4.08).
CONCLUSION: In the early months of the COVID-19 pandemic, patients with RA, PsA, AS, and SLE frequently avoided office visits and laboratory testing. DMARD interruptions commonly occurred without the advice of a physician and were associated with SES, office visits, and telehealth availability, highlighting the need for adequate healthcare access and attention to vulnerable populations during the pandemic.
Copyright © 2021 by the Journal of Rheumatology.

Entities:  

Keywords:  COVID-19; antirheumatic drugs; health behavior; rheumatoid arthritis; spondyloarthritis; systemic lupus erythematosus

Mesh:

Substances:

Year:  2020        PMID: 33191284      PMCID: PMC8121899          DOI: 10.3899/jrheum.201017

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  13 in total

1.  High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis.

Authors:  Karen Au; George Reed; Jeffrey R Curtis; Joel M Kremer; Jeffrey D Greenberg; Vibeke Strand; Daniel E Furst
Journal:  Ann Rheum Dis       Date:  2011-02-02       Impact factor: 19.103

2.  Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study.

Authors:  Alexis Ogdie; YiDing Yu; Kevin Haynes; Thorvardur Jon Love; Samantha Maliha; Yihui Jiang; Andrea B Troxel; Sean Hennessy; Steven E Kimmel; David J Margolis; Hyon Choi; Nehal N Mehta; Joel M Gelfand
Journal:  Ann Rheum Dis       Date:  2014-10-28       Impact factor: 19.103

Review 3.  Digital Interventions to Build a Patient Registry for Rheumatology Research.

Authors:  William Benjamin Nowell; David Curtis; Michelle Thai; Carole Wiedmeyer; Kelly Gavigan; Shilpa Venkatachalam; Seth Ginsberg; Jeffrey R Curtis
Journal:  Rheum Dis Clin North Am       Date:  2019-05       Impact factor: 2.670

Review 4.  The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment.

Authors:  Joachim Listing; Kerstin Gerhold; Angela Zink
Journal:  Rheumatology (Oxford)       Date:  2012-11-28       Impact factor: 7.580

5.  A pneumonia outbreak associated with a new coronavirus of probable bat origin.

Authors:  Peng Zhou; Xing-Lou Yang; Xian-Guang Wang; Ben Hu; Lei Zhang; Wei Zhang; Hao-Rui Si; Yan Zhu; Bei Li; Chao-Lin Huang; Hui-Dong Chen; Jing Chen; Yun Luo; Hua Guo; Ren-Di Jiang; Mei-Qin Liu; Ying Chen; Xu-Rui Shen; Xi Wang; Xiao-Shuang Zheng; Kai Zhao; Quan-Jiao Chen; Fei Deng; Lin-Lin Liu; Bing Yan; Fa-Xian Zhan; Yan-Yi Wang; Geng-Fu Xiao; Zheng-Li Shi
Journal:  Nature       Date:  2020-02-03       Impact factor: 69.504

6.  Experiences of Patients With Rheumatic Diseases in the United States During Early Days of the COVID-19 Pandemic.

Authors:  Kaleb Michaud; Kristin Wipfler; Yomei Shaw; Teresa A Simon; Adam Cornish; Bryant R England; Alexis Ogdie; Patricia Katz
Journal:  ACR Open Rheumatol       Date:  2020-04-20

7.  Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.

Authors:  Milena Gianfrancesco; Kimme L Hyrich; Jinoos Yazdany; Pedro M Machado; Philip C Robinson; Sarah Al-Adely; Loreto Carmona; Maria I Danila; Laure Gossec; Zara Izadi; Lindsay Jacobsohn; Patricia Katz; Saskia Lawson-Tovey; Elsa F Mateus; Stephanie Rush; Gabriela Schmajuk; Julia Simard; Anja Strangfeld; Laura Trupin; Katherine D Wysham; Suleman Bhana; Wendy Costello; Rebecca Grainger; Jonathan S Hausmann; Jean W Liew; Emily Sirotich; Paul Sufka; Zachary S Wallace
Journal:  Ann Rheum Dis       Date:  2020-05-29       Impact factor: 19.103

Review 8.  COVID-19 infection and rheumatoid arthritis: Faraway, so close!

Authors:  Ennio Giulio Favalli; Francesca Ingegnoli; Orazio De Lucia; Gilberto Cincinelli; Rolando Cimaz; Roberto Caporali
Journal:  Autoimmun Rev       Date:  2020-03-20       Impact factor: 9.754

9.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.

Authors:  Zunyou Wu; Jennifer M McGoogan
Journal:  JAMA       Date:  2020-04-07       Impact factor: 56.272

10.  Widening Disparities Among Patients With Rheumatic Diseases in the COVID-19 Era: An Urgent Call to Action.

Authors:  Candace H Feldman; Rosalind Ramsey-Goldman
Journal:  Arthritis Rheumatol       Date:  2020-08-09       Impact factor: 15.483

View more
  22 in total

1.  Anxiety and concerns related to the work situation during the second wave of the COVID-19 pandemic in >5000 patients with inflammatory rheumatic disease followed in the DANBIO registry.

Authors:  Bente Glintborg; Dorte Vendelbo Jensen; Sara Engel; Lene Terslev; Mogens Pfeiffer Jensen; Oliver Hendricks; Mikkel Østergaard; Simon Horskjær Rasmussen; Thomas Adelsten; Ada Colic; Kamilla Danebod; Malene Kildemand; Anne Gitte Loft; Heidi Lausten Munk; Jens Kristian Pedersen; René Drage Østgård; Christian Møller Sørensen; Niels Steen Krogh; Jette Nørgaard Agerbo; Connie Ziegler; Merete Lund Hetland
Journal:  RMD Open       Date:  2021-05

2.  Disruptions in Rheumatology Care and the Rise of Telehealth in Response to the COVID-19 Pandemic in a Community Practice-Based Network.

Authors:  Michael D George; Maria I Danila; Daniel Watrous; Shanmugapriya Reddy; Jeffrey Alper; Fenglong Xie; W Benjamin Nowell; Joel Kallich; Cassie Clinton; Kenneth G Saag; Jeffrey R Curtis
Journal:  Arthritis Care Res (Hoboken)       Date:  2021-07-06       Impact factor: 5.178

Review 3.  Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era.

Authors:  Stefan Schreiber; Shomron Ben-Horin; Rieke Alten; René Westhovens; Laurent Peyrin-Biroulet; Silvio Danese; Toshifumi Hibi; Ken Takeuchi; Fernando Magro; Yoorim An; Dong-Hyeon Kim; SangWook Yoon; Walter Reinisch
Journal:  Adv Ther       Date:  2022-01-06       Impact factor: 4.070

4.  Telemedicine Visits During COVID-19 Improved Clinic Show Rates.

Authors:  Reem Alkilany; Yasir Tarabichi; Raymond Hong
Journal:  ACR Open Rheumatol       Date:  2021-11-17

5.  Real-world evidence for subcutaneous infliximab (CT-P13 SC) treatment in patients with psoriatic arthritis during the coronavirus disease (COVID-19) pandemic: A case series.

Authors:  Xenofon Baraliakos; Styliani Tsiami; Sooraj Vijayan; Haewon Jung; Nick Barkham
Journal:  Clin Case Rep       Date:  2022-01-20

6.  Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey.

Authors:  Sebastian Eduardo Sattui; Jean W Liew; Jonathan S Hausmann; Julia F Simard; Jeffrey A Sparks; Kevin Kennedy; Emily Sirotich; Michael Putman; Tarin T Moni; Akpabio Akpabio; Deshiré Alpízar-Rodríguez; Francis Berenbaum; Inita Bulina; Richard Conway; Aman Dev Singh; Eimear Duff; Karen L Durrant; Tamer A Gheita; Catherine L Hill; Richard A Howard; Bimba F Hoyer; Evelyn Hsieh; Lina El Kibbi; Adam Kilian; Alfred Hyoungju Kim; David F L Liew; Chieh Lo; Bruce Miller; Serena Mingolla; Michal Nudel; Candace A Palmerlee; Jasvinder A Singh; Namrata Singh; Manuel Francisco Ugarte-Gil; John Wallace; Kristen J Young; Suleman Bhana; Wendy Costello; Rebecca Grainger; Pedro M Machado; Philip C Robinson; Paul Sufka; Zachary S Wallace; Jinoos Yazdany; Carly Harrison; Maggie Larché; Mitchell Levine; Gary Foster; Lehana Thabane; Lisa G Rider
Journal:  RMD Open       Date:  2021-09

7.  Real-world evidence for subcutaneous infliximab (CT-P13 SC) treatment in patients with ankylosing spondylitis during the coronavirus disease (COVID-19) pandemic: A case series.

Authors:  Sooraj Vijayan; Kyungmin Hwangbo; Nick Barkham
Journal:  Clin Case Rep       Date:  2022-01-13

8.  Evaluation of a Non-Face-to-Face Multidisciplinary Health Care Model in a Population with Rheumatoid Arthritis Vulnerable to COVID-19 in a Health Emergency Situation.

Authors:  Pedro Santos-Moreno; Gabriel-Santiago Rodríguez-Vargas; Rosangela Casanova; Jaime-Andrés Rubio-Rubio; Josefina Chávez-Chávez; Diana Patricia Rivera-Triana; Ruth Alexandra Castiblanco-Montañez; Sandra Milena Hernández-Zambrano; Laura Villareal; Adriana Rojas-Villarraga
Journal:  Healthcare (Basel)       Date:  2021-12-17

9.  Quality of life of patients with rheumatic diseases during the COVID-19 pandemic: The biopsychosocial path.

Authors:  Guillermo A Guaracha-Basáñez; Irazú Contreras-Yáñez; Gabriela Hernández-Molina; Viviana A Estrada-González; Lexli D Pacheco-Santiago; Salvador S Valverde-Hernández; José Roberto Galindo-Donaire; Ingris Peláez-Ballestas; Virginia Pascual-Ramos
Journal:  PLoS One       Date:  2022-01-18       Impact factor: 3.240

10.  Psychological Effects of Lockdown Measures for the COVID-19 Outbreak in Patients with Systemic Lupus Erythematosus.

Authors:  Luca Quartuccio; Ginevra De Marchi; Danila Azzolina; Elisabetta Maresio; Donatella Colatutto; Marco Binutti; Marinella Monte; Silvia Gallipoli; Federica Zobec; Corrado Lanera; Giulia Lorenzoni; Alvisa Palese; Marco Silano; Salvatore De Vita; Dario Gregori
Journal:  J Multidiscip Healthc       Date:  2021-06-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.